

## **POLISH FINANCIAL SUPERVISION AUTHORITY**

Current Report no. 10/2024

Date of preparation: 2024-06-26

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of cooperation with Novavax, Inc. and conclusion of an annex to the quality agreement

Legal basis: Article 17(1) of MAR – confidential information

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion, with Novavax, Inc. ("Novavax"), of a commercial contract manufacturing agreement ("Manufacturing Agreement") and subsequent Current Reports regarding the expansion of cooperation with Novavax, the Management Board of Mabion S.A. ("Company") hereby informs that on 26 June 2024, it signed with Novavax a further extension to the scope of services provided under the Manufacturing Agreement, in the form of Statement of Work #11 ("SOW#11").

Under SOW#11, the Company is to carry out work related to the development and validation of a new analytical method based on peptide mapping technology, followed by regular contract testing of samples using this method. SOW#11 relates to research associated with Novavax's new product, the COVID-influenza combination ('CIC') vaccine. SOW#11 stipulates the possibility of extending the tests to include new product variants. Routine testing of samples from products in development and commercial products will be carried out in a GMP- (Good Manufacturing Practice) compliant environment.

While the financial value of SOW#11 itself is not relevant for the assessment of the materiality of the order for the Company, the extension of the cooperation with Novavax into another new area represents an important and key business value.

In connection with the execution of SOW#11, the parties signed an annex to their binding quality agreement, as referred to in Current Report no. 63/2021 of 19 November 2021. Under the annex to the quality agreement, the parties extended the list of products analysed at Mabion to include the CIC vaccine.